Syntara has received a milestone payment of approximately A$1.7 million (£900,000) from Parkinson’s UK, triggered by dosing of the final patient in its Phase 2 clinical trial of SNT-4728.
The payment forms part of Parkinson’s UK’s funding commitment to support the development of SNT-4728, which is being evaluated as a potential treatment targeting neuroinflammation associated with early-stage Parkinson’s disease.
The Phase 2 trial is evaluating SNT-4728 in individuals diagnosed with isolated REM sleep behaviour disorder (iRBD), a condition recognised as one of the strongest known early indicators of future Parkinson’s disease and related neurodegenerative disorders. More than 80% of iRBD patients go on to develop Parkinson’s disease and the related disorders dementia with Lewy bodies and multiple system atrophy.
Top-line results from the trial, including both safety and efficacy endpoints, are expected in Q2 CY26. Syntara will be eligible to receive a further A$0.45 million (£250,000) milestone payment from Parkinson’s UK upon project completion. The global addressable market for iRBD is estimated at US$1.6b and for Parkinson’s disease at US$9.2b by 2030.
